Health Secretary Robert F. Kennedy Jr. and other Trump officials are signaling their interest in approving psychedelic drugs for hard-to-treat mental health conditions.

Researchers conducted the QWINT-1 and QWINT-2 clinical trials to assess glycemic and patient-reported outcomes among those using once-weekly insulin efsitora.